NASDAQ:ARDX - Ardelyx Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.79 -0.16 (-5.42 %)
(As of 11/13/2018 04:00 PM ET)
Previous Close$2.95
Today's Range$2.76 - $3.11
52-Week Range$2.66 - $8.10
Volume591,200 shs
Average Volume432,271 shs
Market Capitalization$188.89 million
P/E Ratio-2.10
Dividend YieldN/A
Beta1.33
Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells disruptive medicines for the treatment of cardio renal and gastrointestinal diseases in the United States and Asia Pacific. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia; RDX8940, an oral TGR5 agonist; RDX011, a NHE3 inhibitor; and RDX023 program for the development of gut-biased farnesoid X receptor agonists. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

Receive ARDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARDX
Previous Symbol
CUSIPN/A
Phone510-745-1700

Debt

Debt-to-Equity Ratio0.35
Current Ratio12.83
Quick Ratio12.83

Price-To-Earnings

Trailing P/E Ratio-2.10
Forward P/E Ratio-1.73
P/E GrowthN/A

Sales & Book Value

Annual Sales$42 million
Price / Sales4.13
Cash FlowN/A
Price / CashN/A
Book Value$2.93 per share
Price / Book0.95

Profitability

EPS (Most Recent Fiscal Year)($1.36)
Net Income$-64,330,000.00
Net MarginsN/A
Return on Equity-37.22%
Return on Assets-28.98%

Miscellaneous

Employees75
Outstanding Shares62,130,000
Market Cap$188.89 million
OptionableOptionable

Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

How were Ardelyx's earnings last quarter?

Ardelyx Inc (NASDAQ:ARDX) issued its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.41) by $0.02. View Ardelyx's Earnings History.

When is Ardelyx's next earnings date?

Ardelyx is scheduled to release their next quarterly earnings announcement on Wednesday, March 13th 2019. View Earnings Estimates for Ardelyx.

What price target have analysts set for ARDX?

6 analysts have issued 12-month price targets for Ardelyx's shares. Their predictions range from $7.00 to $16.00. On average, they expect Ardelyx's share price to reach $11.8333 in the next year. This suggests a possible upside of 324.1% from the stock's current price. View Analyst Price Targets for Ardelyx.

What is the consensus analysts' recommendation for Ardelyx?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ardelyx.

Has Ardelyx been receiving favorable news coverage?

Media coverage about ARDX stock has trended neutral recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ardelyx earned a daily sentiment score of 0.4 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term.

Who are some of Ardelyx's key competitors?

Who are Ardelyx's key executives?

Ardelyx's management team includes the folowing people:
  • Mr. Michael G. Raab, Pres, CEO & Director (Age 53)
  • Mr. David Rosenbaum, Chief Devel. Officer (Age 57)
  • Mr. Mark E. Kaufmann, CFO & Treasurer (Age 50)
  • Mr. Bryan Shaw, Chief Accounting Officer, VP and Controller (Age 64)
  • Mr. Jeffrey W. Jacobs, Sr. VP of Technical Operations (Age 55)

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.25%), Dimensional Fund Advisors LP (2.53%), Pekin Singer Strauss Asset Management IL (1.61%), GSA Capital Partners LLP (0.26%), Bridgeway Capital Management Inc. (0.25%) and Connor Clark & Lunn Investment Management Ltd. (0.19%). Company insiders that own Ardelyx stock include David P Rosenbaum, Forest Baskett, Gordon Ringold, Jeremy S Caldwell, Reginald Seeto and Scott D Sandell. View Institutional Ownership Trends for Ardelyx.

Which institutional investors are selling Ardelyx stock?

ARDX stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for Ardelyx.

Which institutional investors are buying Ardelyx stock?

ARDX stock was purchased by a variety of institutional investors in the last quarter, including Pekin Singer Strauss Asset Management IL, BlackRock Inc., Dimensional Fund Advisors LP, Panagora Asset Management Inc., Bridgeway Capital Management Inc., Alps Advisors Inc. and ClariVest Asset Management LLC. View Insider Buying and Selling for Ardelyx.

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $2.79.

How big of a company is Ardelyx?

Ardelyx has a market capitalization of $188.89 million and generates $42 million in revenue each year. The biopharmaceutical company earns $-64,330,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Ardelyx employs 75 workers across the globe.

What is Ardelyx's official website?

The official website for Ardelyx is http://www.ardelyx.com.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]


MarketBeat Community Rating for Ardelyx (NASDAQ ARDX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  266 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  459
MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe ARDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel